Our observations support the rationale for IL-23–targeted agents in patients with overlapping psoriasis and inflammatory bowel disease, and they provide exploratory evidence that the psoriasis-labeled regimen of GUS may suffice for selected UC patients. Here, IL23A is linked to psoriasis.